Introduction Takeda is a patient-centric, value-based global biopharmaceutical company powered by research and development. Committed to advancing breakthrough science for global patients, Takeda focuses on drug R&D in oncology, gastroenterology, neuroscience, and rare diseases, with targeted investment in hematology and vaccines. Since entering China in 1994, Takeda's China headquarters is based in Shanghai, with key business hubs in Beijing, Shanghai, Tianjin, Guangzhou, and the Hong Kong SAR, serving patients nationwide. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Recombinant coagulation factor | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism UL97 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date23 Nov 2021 |
Target |
Mechanism vWF stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date08 Dec 2015 |
Target |
Mechanism F10 stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date13 Nov 2015 |
Start Date15 Dec 2024 |
Sponsor / Collaborator Catalent CTS LLC [+3] |
Start Date20 Jul 2024 |
Sponsor / Collaborator |
Start Date24 Jun 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Maribavir ( UL97 ) | Cytomegalovirus Infections More | Approved |
Vonicog Alfa (Baxalta) ( vWF ) | Von Willebrand Diseases More | Approved |
Soticlestat ( CH24H ) | Status Epilepticus More | Phase 3 |
Mezagitamab ( CD38 ) | Purpura, Thrombocytopenic, Idiopathic More | Phase 2 |
TAK-676 ( STING ) | Colorectal Cancer More | Phase 1 |